The international BIO-Europe® 2021 gathering will be held digitally on October 25-28. The virtual event will bring together global biopharma and investment leaders to build partnerships that facilitate innovation and medical breakthroughs. BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.
Mogrify® has developed a proprietary suite of platform that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). Mogrify is applying its proprietary and award-winning platforms to engineer a renewable and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.